MENU
+Compare
IDNA
ETF ticker: NYSE ARCA
AS OF
Jul 25 closing price
Price
$22.18
Change
-$0.09 (-0.40%)
Net Assets
114.54M

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IDNA with price predictions
Jul 25, 2025

IDNA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IDNA turned positive on July 09, 2025. Looking at past instances where IDNA's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on IDNA as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 199 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

IDNA broke above its upper Bollinger Band on July 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.

Market Cap

The average market capitalization across the iShares Genomics Immnlgy & Hlthcr ETF ETF is 18.87B. The market cap for tickers in the group ranges from 143.71M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is SGMO at 143.71M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was 4%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was -1%. IOVA experienced the highest price growth at 40%, while LGND experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immnlgy & Hlthcr ETF ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was 8% and the average quarterly volume growth was 36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 78
Price Growth Rating: 53
SMR Rating: 85
Profit Risk Rating: 89
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
IDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com